Search

You searched for "transperineal"

281 results found
BJUI International journal cover image.

Curing pure CIS with radical surgery: lessons learned

1 September 2014 | | URO - Urologic Oncology
As carcinoma in situ (CIS) theoretically has no ability to invade or metastasise, performing radical cystectomy for CIS-only disease should be curative. In this single centre review over 37 years, 1964 patients undergoing cystectomy were analysed with 52 undergoing surgery...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

12 October 2022 | | URO - Urologic Oncology
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

Outcomes of sarcomatoid differentiation in urothelial carcinoma

5 December 2022 | | URO - Urologic Oncology
Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...
BJUI journal cover image.

Effect of DUA on surgical outcomes of HoLEP

8 January 2025 | | URO - Functional / Reconstructive Urology, URO - Infection
Lower urinary tract symptoms (LUTS) become increasingly common in men as they age, with over 70–90% of men aged over 80 experiencing these issues. Detrusor underactivity (DUA) is characterised by a weakened bladder contraction, leading to prolonged or incomplete bladder...

The History Display BAUS 2026

7 May 2026 | | URO - Technology
The Museum of Urology at BAUS History Display is back! Whilst the BAUS annual meeting was held in Birmingham it had not been possible to put on the display of instruments and artefacts, which had previously been a fixture at...
European Urology journal front cover.

The future of bladder preservation for muscle-invasive bladder cancer

3 July 2026 | | URO - Functional / Reconstructive Urology, URO - Urologic Oncology
Localised muscle-invasive bladder cancer (MIBC) has historically been treated with radical cystectomy (RC), but bladder preservation therapy (BPT) has emerged as a credible and increasingly refined alternative. Early work by Herr in the 1980s demonstrated that radical transurethral resection of...

Metabolic screening and stone-prevention in urolithiasis patients

1 July 2017 | | URO - Endourology & Stones
The incidence and prevalence of kidney stones is increasing [1,2]. Significant recurrence rates are noted with 14% of patients experiencing a further episode at one year, 35% at five years, and 52% at 10 years [3]. Over 10% of stone...

Focal therapy trials

6 November 2020 | | URO - Urologic Oncology
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...

An account of training and practice of urology in Nigeria

3 May 2022 |
Nigeria is the most populous nation on the continent of Africa. Within the country, there are 33,303 general hospitals and 59 tertiary hospitals to serve a population of approximately 210 million people [1]. Specialty-based practice of urology is domiciled in...

Innovations in urology – OOPE for trainees

3 November 2022 | | URO - Technology
“Innovation is the ability to see change as an opportunity – not a threat” – Steve Jobs [1] The world is changing rapidly. Healthcare has seen a fast reform, especially as a consequence of COVID-19. Urology is a rapidly evolving...

Biomarkers in prostate cancer detection

1 July 2018 | | URO - Basic Science Research, URO - Urologic Oncology, URO - Technology
Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

Improving on the Rotterdam Prostate Cancer Risk Calculator

1 January 2019 | | URO - Technology
Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...